Our flexible cyclodextrin technology can be applied to a multitude of other molecular targets. These targets may include toxic metabolites accumulating in lysosomal storage diseases or more common disease states and pharmaceutical targets. Collaboration with pharmaceutical companies enables us to share our expertise with our partners and design and develop novel cyclodextrins in multiple therapeutic areas.
Please contact us if you want to explore custom designed cyclodextrins for a target you are interested in or if you want to screen our cyclodextrin library in your in vitro assays.
Okklo seeks to partner its current own programs with pharmaceutical companies early in the development process. As such, we are actively looking for co-development partners for our current cardiovascular and Niemann-Pick type C disease programs.
In addition, we are exploring new programs on hematology, lysosomal storage diseases, oncology and neurodegenerative diseases.